(Q53197894)

12 May 2018

title

Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis. (English)

1 reference

12 May 2018

1 reference

M Tandon

1

1 reference

12 May 2018

Z Chen

series ordinal

2

1 reference

12 May 2018

A H Othman

series ordinal

3

1 reference

12 May 2018

J Pratap

series ordinal

4

1 reference

12 May 2018

language of work or name

English

0 references

publication date

25 January 2016

1 reference

12 May 2018

published in

Oncogene

1 reference

12 May 2018

volume

35

1 reference

12 May 2018

issue

36

1 reference

12 May 2018

page(s)

4730-4740

1 reference

12 May 2018

https://scigraph.springernature.com/pub.10.1038/onc.2015.518

exact match

0 references

cites work

The clinical course of bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Mechanisms of osteolytic bone destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Dissemination and growth of cancer cells in metastatic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Molecular biology of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Receptor activator of nuclear factor kappa B ligand (RANKL): another link between breast and bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: implications for breast cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Runx2 in human breast carcinoma: its potential roles in cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

The RUNX family in breast cancer: relationships with estrogen signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Mechanisms of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

IGF1R signalling and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Interference of the IGF system as a strategy to inhibit breast cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Metabolic pathways promoting cancer cell survival and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Role of Runx2 in crosstalk between Mek/Erk and PI3K/Akt signaling in MCF-10A cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Grb10/Nedd4-mediated multiubiquitination of the insulin-like growth factor receptor regulates receptor internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Regulation of the Warburg effect in early-passage breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

AMPK: a contextual oncogene or tumor suppressor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

The AMPK inhibitor compound C is a potent AMPK-independent antiglioma agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

S6K is a morphogenic protein with a mechanism involving Filamin-A phosphorylation and phosphatidic acid binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

EGFR signaling in breast cancer: bad to the bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Bone metastasis: mechanisms and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Examining the metastatic niche: targeting the microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Critical nodes in signalling pathways: insights into insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Insulin-like growth factor receptor inhibitors: baby or the bathwater?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Two domains unique to osteoblast-specific transcription factor Osf2/Cbfa1 contribute to its transactivation function and its inability to heterodimerize with Cbfbeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Transcriptional co-repressors of Runx2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Transcriptional regulation of osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Post-translational Regulation of Runx2 in Bone and Cartilage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Glucocorticoids regulate arrestin gene expression and redirect the signaling profile of G protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Runx2 recruits p300 to mediate parathyroid hormone's effects on histone acetylation and transcriptional activation of the matrix metalloproteinase-13 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

A RUNX2-HDAC1 co-repressor complex regulates rRNA gene expression by modulating UBF acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Genomic occupancy of Runx2 with global expression profiling identifies a novel dimension to control of osteoblastogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Identification and functional characterization of ERK/MAPK phosphorylation sites in the Runx2 transcription factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

AMP-activated protein kinase promotes human prostate cancer cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Metformin in cancer treatment and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Understanding the benefit of metformin use in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Recent advances in the use of metformin: can treating diabetes prevent breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

A stress response pathway regulates DNA damage through β2-adrenoreceptors and β-arrestin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

A multigenic program mediating breast cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

TRANSFAC, TRRD and COMPEL: towards a federated database system on transcriptional regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Identification of novel protein/DNA interactions within the promoter of the bone-related transcription factor Runx2/Cbfa1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

A new emergency in oncology: Bone metastases in breast cancer patients (Review)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Models of bone metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Bone matrix quality after sclerostin antibody treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.518

Runx2/Cbfa1 functions: diverse regulation of gene transcription by chromatin remodeling and co-regulatory protein interactions

31 March 2020

1 reference

12 December 2020

1 reference

12 December 2020

Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts

1 reference

12 December 2020

A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer.

1 reference

12 December 2020

Identifiers

DOI

10.1038/ONC.2015.518

1 reference

12 May 2018

Dimensions Publication ID

0 references

1 reference

12 May 2018